ES8608884A1 - Un procedimiento de eliminacion del virus lav. - Google Patents

Un procedimiento de eliminacion del virus lav.

Info

Publication number
ES8608884A1
ES8608884A1 ES546974A ES546974A ES8608884A1 ES 8608884 A1 ES8608884 A1 ES 8608884A1 ES 546974 A ES546974 A ES 546974A ES 546974 A ES546974 A ES 546974A ES 8608884 A1 ES8608884 A1 ES 8608884A1
Authority
ES
Spain
Prior art keywords
elimination
procedure
lav
virus lav
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES546974A
Other languages
English (en)
Other versions
ES546974A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Publication of ES546974A0 publication Critical patent/ES546974A0/es
Publication of ES8608884A1 publication Critical patent/ES8608884A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROCEDIMIENTO PARA LA ELIMINACION DEL VIRUS LAV CONTENIDO EN EL PLASMA DE UN PACIENTE. CONSISTE EN HACER PASAR EL PLASMA AFECTADO POR UNA COLUMNA DE AFINIDAD QUE LLEVA MOLECULAS T4 Y EN RECOGER EL PLASMA LIBERADO DE VIRUS LAV. DICHA COLUMNA PORTADORA DE MOLECULAS T4 PUEDE SERVIR IGUALMENTE PARA ATRAPAR LOS ANTICUERPOS ANTI-T4 RESULTANTES DE UN MECANISMO AUTOINMUNITARIO IMPLICADOS EN LA ENFERMEDAD. LOS ANTICUERPOS ANTI-T4 ATRAPADOS DE ESTA MANERA, ESTAN CONSTITUIDOS EN GENERAL POR AUTOANTICUERPOS PRESENTE EN EL PLASMA. DE APLICACION EN LA PROTECCION DE LOS LINFOCITOS T CONTRA LOS AGENTES ETIOLOGICOS DE LAS LINFADENOPATIAS Y DEL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA.
ES546974A 1984-09-14 1985-09-13 Un procedimiento de eliminacion del virus lav. Expired ES8608884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8414172A FR2570278B1 (fr) 1984-09-14 1984-09-14 Compositions et procede pour proteger les lymphocytes t contre l'agent etiologique des lymphadenopathies et du syndrome d'immunodepression acquise

Publications (2)

Publication Number Publication Date
ES546974A0 ES546974A0 (es) 1986-09-01
ES8608884A1 true ES8608884A1 (es) 1986-09-01

Family

ID=9307750

Family Applications (1)

Application Number Title Priority Date Filing Date
ES546974A Expired ES8608884A1 (es) 1984-09-14 1985-09-13 Un procedimiento de eliminacion del virus lav.

Country Status (8)

Country Link
EP (1) EP0176429B1 (es)
JP (2) JP2783403B2 (es)
AT (1) ATE58478T1 (es)
CA (1) CA1273304A (es)
DE (2) DE3583400D1 (es)
ES (1) ES8608884A1 (es)
FR (1) FR2570278B1 (es)
OA (1) OA08099A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2592893A1 (fr) * 1986-01-15 1987-07-17 Pasteur Institut Population de lymphocytes t4 specifiques du virus lav, leur procede d'obtention et leur application a la production de ce virus.
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
WO1989004672A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company Derivatives of lincosaminide antibiotics
ATE85215T1 (de) * 1987-12-19 1993-02-15 Experimentelle Chirurgie Lab Antivirales therapeutikum.
DE3828582A1 (de) * 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
EP0408372A1 (en) * 1989-07-13 1991-01-16 Smithkline Beecham Corporation Anti-viral therapy
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
RU2121852C1 (ru) * 1997-12-25 1998-11-20 Акционерное общество закрытого типа "Научно-производственное предприятие "Олифен" Композиция, оптимизирующая жизнедеятельность клеток и клеточных систем организма в неблагоприятных условиях
RU2208442C1 (ru) * 2002-04-22 2003-07-20 Восточно-Сибирский государственный технологический университет Комплексное иммунокорригирующее средство
CN106075626B (zh) * 2016-07-01 2018-06-26 浙江大学 一种艾滋病血液净化治疗仪
CN106166313B (zh) * 2016-07-01 2018-09-07 浙江大学 一种艾滋病孕妇血液净化器

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation

Also Published As

Publication number Publication date
DE3580639D1 (de) 1991-01-03
ATE58478T1 (de) 1990-12-15
OA08099A (fr) 1987-03-31
EP0176429B1 (fr) 1990-11-22
ES546974A0 (es) 1986-09-01
JP2783403B2 (ja) 1998-08-06
JPH0912462A (ja) 1997-01-14
JPS61143328A (ja) 1986-07-01
FR2570278B1 (fr) 1987-02-13
EP0176429A1 (fr) 1986-04-02
FR2570278A1 (fr) 1986-03-21
DE3583400D1 (de) 1991-08-08
CA1273304A (fr) 1990-08-28

Similar Documents

Publication Publication Date Title
EA199901031A1 (ru) Производные бензимидазола
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
ATE38672T1 (de) 7-oxabicycloheptan aminosubstituierte prostaglandinaehnliche verbindungen.
ES8608884A1 (es) Un procedimiento de eliminacion del virus lav.
NL960024I2 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus besmette patiënten.
EP0230574A3 (en) Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
MY104942A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2-ones.
OA07525A (fr) Dérivés d'acides-animés, leur préparation et utilisation ainsi que les compositions contenant ces dérivés.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FI874166A7 (fi) 2',3'-dideoksisytidin-2'-eenin käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DK178188D0 (da) Antivirusmiddel
IT8423517A0 (it) Composizione farmaceutica per combattere infezioni virali, eprocedimento di uso per le infezioni virali.
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.
SE8206128L (sv) Farmaceutisk komposition for behandling av njurstenar framkallade genom infektion
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
MY106961A (en) Antiviral tetrahydroimidazo[1,4] benzodiazepines
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
EP0335426A3 (en) Compositions and process for protecting t lymphocytes against the etiological agent of lymphadenopathy and acquired immunodepression syndrom
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
ES2078380T3 (es) Oligofosfatos de accion antiviral.
ZA896230B (en) Pharmaceutical composition for inhibiting infection with virus causative of acquired human immunodefeciency syndrome
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20020506